| Revenue growth | FY26 revenue at ₹5,059 Mn, up 32% YoY. |
|---|---|
| Margins | EBITDA margin expanded to 18% in FY26 from 9% in FY25. |
| Demand visibility | Recurring demand from non-regenerative catalysts in SDA/PTC. |
Growth
FY26 Revenue grew 32% YoY; EBITDA increased 172% YoY to ₹932 Mn; PAT margins improved from 1.5% to 8.3%.
Outlook
Focus on 'green' chemistry through electrolysis and continuous flow; SDA remains a core growth driver for emission control.
Risks
Industry-wide high barriers to entry (1-6 years for approvals); global geopolitical shifts impacting supply chains.
Earnings Call filed with NSE, NSE: TATVA. Summary written with AI assistance from the document.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,999.80
- Market cap
- ₹4,678 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 91.0×Sector 37.2×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 3.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Business Update
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.
Tatva Chintan Pharma Chem Annual Report
Tatva Chintan Pharma Chem Limited has submitted its Annual Report for the financial year 2025-26. The company's 30th Annual General Meeting is scheduled for September 25, 2026.
Tatva Chintan Pharma Chem Annual General Meeting
Tatva Chintan Pharma Chem Limited has scheduled its 30th Annual General Meeting for September 25, 2026. Key agenda items include dividend declaration and director re-appointments.
Tatva Chintan Pharma Chem Annual General Meeting
Tatva Chintan Pharma Chem Limited scheduled its 30th AGM for September 25, 2026. Key agenda items include dividend declaration and increasing borrowing limits to ₹1,000 Crore.
- Value
- ₹1,000 Cr